ProQR Therapeutics/PRQR

$2.15

2.38%
-
1D1W1MYTD1YMAX

About ProQR Therapeutics

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Ticker

PRQR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel De Boer

Employees

130

Headquarters

Leiden, Netherlands

PRQR Metrics

BasicAdvanced
$165.56M
Market cap
-
P/E ratio
-$0.47
EPS
0.20
Beta
-
Dividend rate

What the Analysts think about PRQR

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
90.23% upside
High $6.06
Low $1.82
$2.15
Current price
$4.09
Average price target

PRQR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-438.46% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
€1.3M
8.33%
Net income
€-5.7M
-27.85%
Profit margin
-438.46%
-33.4%

PRQR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 18.02%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-€0.16
-€0.11
-€0.10
-€0.07
-
Expected
-€0.17
-€0.12
-€0.11
-€0.09
€0.01
Surprise
-8.01%
-6.41%
-9.79%
-18.02%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell ProQR Therapeutics stock

Buy or sell ProQR Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing